SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Northwest Biotherapeutics Inc.
An SI Board Since August 2006
Posts SubjectMarks Bans Symbol
760 18 0 NWBO
Emcee:  John McCarthy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
534Brad Silver, an All American swimming and news-medical.netJohn McCarthy-9/12/2014
533jewishworldreview.com Cancer vaccine offers hope By Carrie Peyton Dahlberg John McCarthy-9/12/2014
532Pauls Battle paulsbattle.orgJohn McCarthy-9/12/2014
531As I think I mentioned, the Specials program at King’s College in London is ovJohn McCarthy-9/12/2014
530Defining pseudoprogression in glioblastoma multiforme. ncbi.nlm.nih.gov currenJohn McCarthy-9/11/2014
529NCBI ncbi.nlm.nih.govJohn McCarthy-9/10/2014
528Link to trials nhs.ukJohn McCarthy-9/10/2014
527German Trial Link drks-neu.uniklinik-freiburg.de England nhs.ukJohn McCarthy-9/10/2014
526What is Pseudo-Progression Following Treatment for Glioblastoma Multiforme?GliobJohn McCarthy-9/10/2014
525Slide 9 Lead Program:DCVax-L for Newly Diagnosed GBM [graphic]John McCarthy-9/10/2014
524Slide 8 DCVax Applicable to All Solid Tumors (Both Operable & Inoperable) [John McCarthy-9/10/2014
523Slide 7 Each "Educated" Dendritic Cell Activates Hundreds of Anti-CancJohn McCarthy-9/10/2014
522Slide 6 Dendritic Cells Mobilize the Whole Immune System [graphic]John McCarthy-9/10/2014
521Slide 5 Strengths of DCVax-L vs. Other Immune Therapies [graphic]John McCarthy-9/10/2014
520Slide 4 [graphic]John McCarthy-9/10/2014
519Slide 3 >80% of patients respond [graphic]John McCarthy-9/10/2014
518Slide 25 [graphic]John McCarthy-9/10/2014
517Slide 24 Cost-Effective, Rapid Batch Manufacturing [graphic]John McCarthy-9/10/2014
516Slide 23 DCVax-Prostate [graphic]John McCarthy-9/9/2014
515Slide 22 DCVax-Direct Case Study: Sarcoma [graphic]John McCarthy-9/9/2014
514Slide 21 Results to Date in DCVax-Direct Ohase I/II Trial [graphic]John McCarthy-9/9/2014
513Slide 20 DCVax-Direct Phase I/II Trial Design [graphic]John McCarthy-9/9/2014
512Slide 19 DCVax-Direct:Striking Pre-Clinical Results [graphic]John McCarthy-9/9/2014
511Slide 18 DCVax Direct:Potential Clinical Effects [graphic]John McCarthy-9/9/2014
510Slide 17 Novel Technology [graphic]John McCarthy-9/9/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News